Skinvisible licensee Quoin reports positive Netherton Syndrome clinical results; $5M milestone payment upon approval

SKINVISIBLE, INC.

Quoin's QRX003 (using Invisicare) showed 'severe' to 'mild' improvement after 6 weeks in Netherton Syndrome studies.
FDA cleared a whole-body study at Northwestern University; no adverse events reported to date.
Clinical trials expanded to UK, Ireland, and Saudi Arabia; product licensed in 60 countries.
Skinvisible to receive $5M milestone payment plus ongoing royalties upon FDA or EU approval.
Skinvisible actively seeking partnerships for transdermal obesity therapies and other formulations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.